[ad_1]
Original title: Tight EU control on the export of vaccines from the new crown Macron: The United States and the United Kingdom control how we can be “naive” Source: CCTV News Client
The new corona pneumonia epidemic in Europe is once again serious and, in this circumstance, the EU and the United Kingdom continue to clash over the new corona vaccine. A few days ago, the European Union revised the crown’s new vaccine export management regulations to strengthen the control and control of vaccine exports. In this sense, some British media accused the actions of the EU as “selfish”. On the 25th, French President Macron replied that the relevant regulations were formulated by the European Union with reference to the attitude of the United States and the United Kingdom to restrict exports of vaccines.
The new corona pneumonia epidemic in Europe is once again serious and, in this circumstance, the EU and the United Kingdom continue to clash over the new corona vaccine. A few days ago, the European Union revised the crown’s new vaccine export management regulations to strengthen the control and control of vaccine exports. In this sense, some British media accused the actions of the EU as “selfish”. On the 25th, French President Macron replied that the relevant regulations were formulated by the European Union with reference to the attitude of the United States and the United Kingdom to restrict exports of vaccines.
Macron told a press conference on the 25th that the EU’s move to strengthen export control of the crown’s new pneumonia vaccine is not “selfish.” The European Union is aware of the so-called “domestic market priority” in the United States, and the United Kingdom also restricts exports of vaccines.
Macron said that in such circumstances, the EU can no longer be “naive”. The purpose of the European Commission is to force vaccine manufacturers, especially AstraZeneca Pharmaceuticals, to deliver the doses that they agreed to in the contract.
At the end of January this year, AstraZeneca stated that due to capacity limitations, it would significantly reduce the number of vaccines delivered to the European Union in the first quarter of this year. The European Union was very unhappy with this and once threatened to use the terms of the “Brexit” deal to restrict the export of the new crown vaccine to the UK.
On the 25th, the European Union requested AstraZeneca to expedite the delivery of the new corona vaccine to the EU to make up the current supply gap. The company must export vaccines to regions outside the EU only after fulfilling the vaccine supply contract signed with the European Union. AstraZeneca is said to have delivered 90 million doses of the new crown vaccine to the EU in the first quarter of this year, but the current delivery volume is only 30%.
(Edited by Qiu Jing)
Macron told a press conference on the 25th that the EU’s move to strengthen export control of the crown’s new pneumonia vaccine is not “selfish.” The European Union is aware of the so-called “domestic market priority” in the United States, and the United Kingdom also restricts exports of vaccines.
Macron said that in such circumstances, the EU can no longer be “naive”. The purpose of the European Commission is to force vaccine manufacturers, especially AstraZeneca Pharmaceuticals, to deliver the doses that they agreed to in the contract.
At the end of January this year, AstraZeneca stated that due to capacity limitations, it would significantly reduce the number of vaccines delivered to the European Union in the first quarter of this year. The European Union was very unhappy with this and once threatened to use the terms of the “Brexit” deal to restrict the export of the new crown vaccine to the UK.
On the 25th, the European Union requested AstraZeneca to expedite the delivery of the new corona vaccine to the EU to make up the current supply gap. The company must export vaccines to regions outside the EU only after fulfilling the vaccine supply contract signed with the European Union. AstraZeneca is said to have delivered 90 million doses of the new crown vaccine to the EU in the first quarter of this year, but the current delivery volume is only 30%.
(Edited by Qiu Jing)
